Oravig

Oravig is a brand name of miconazole, approved by the FDA in the following formulation(s):

ORAVIG (miconazole - tablet; buccal)

• 
  Manufacturer: BIOALLIANCE PHARMA
  
  Approval date: April 16, 2010
  
  Strength(s): 50MG ^[RLD]

Has a generic version of Oravig been approved?

No. There is currently no therapeutically equivalent version of Oravig available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oravig. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Prolonged release bioadhesive therapeutic systems
  Patent 6,916,485
  Issued: July 12, 2005
  Inventor(s): Aiache; Jean-Marc & Costantini; Dominique & Chaumont; Christine
  Assignee(s): Bioalliance Pharma
  The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active dissolution test of more than 70% over 8 hours and to a method for its preparation. The bioadhesive therapeutic system may be in tablet form and may contain quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of the tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and may contain between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.
  
  Patent expiration dates:
  
  
  • September 11, 2022
    
    ✓ 
    Patent use: TREATMENT OF OROPHARYNGEAL CANDIDIASIS
    ✓ 
    Drug product
  
  



• 
  Prolonged release bioadhesive therapeutic systems
  Patent 7,651,698
  Issued: January 26, 2010
  Inventor(s): Aiache; Jean-Marc & Costantini; Dominique & Chaumont; Christine
  Assignee(s): Bioalliance Pharma
  The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. This bioadhesive therapeutic system comprises quantities of natural proteins representing 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.
  
  Patent expiration dates:
  
  
  • January 8, 2026
    
    ✓ 
    Patent use: TREATMENT OF OROPHARYNGEAL CANDIDIASIS
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 16, 2013 - NEW DOSAGE FORM
  
  

See also...

• Oravig Consumer Information (Drugs.com)
• Oravig Consumer Information (Wolters Kluwer)
• ORAVIG buccal Consumer Information (Cerner Multum)
• Miconazole Consumer Information (Wolters Kluwer)
• Miconazole oral buccal Consumer Information (Cerner Multum)